UGT1A1*6,1A7*3, and1A9*22genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan-Reference-Cited by-同舟云学术

UGT1A1*6,1A7*3, and1A9*22genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan

Published:2013-10-27 Issue:12 Volume:104 Page:1662-1669
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Hazama Shoichi¹,Mishima Hideyuki²,Tsunedomi Ryouichi¹,Okuyama Yusuke³,Kato Takeshi⁴,Takahashi Ken-ichi⁵,Nozawa Hiroshi⁶,Ando Hideaki⁷,Kobayashi Michiya⁸,Takemoto Hiroyoshi⁹,Nagata Naoki¹⁰,Kanekiyo Shinsuke¹,Inoue Yuka¹,Hamamoto Yoshihiko¹¹,Fujita Yusuke¹¹,Hinoda Yuji¹²,Okayama Naoko¹²,Oba Koji¹³,Sakamoto Jun-ichi¹⁴,Oka Masaaki¹

Affiliation:

1. Department of Digestive Surgery and Surgical Oncology (Surgery II); Yamaguchi University Graduate School of Medicine; Ube Japan

2. Cancer Center; Aichi Medical University; Nagakute Japan

3. Department of Digestive Medicine; Kyoto First Red Cross Hospital; Kyoto Japan

4. Department of Surgery; Kansai Rosai Hospital; Osaka Japan

5. Department of Surgery; Aomori Prefectural Hospital; Aomori Japan

6. Nozawa Clinic; Imizu Japan

7. Program for the Strategic Education of Future Surgeons; Akita University Graduate School of Medicine; Akita Japan

8. Cancer Treatment Center; Kochi Medical School; Kochi Japan

9. Department of Surgery; Kinki Central Hospital; Osaka Japan

10. Department of Surgery; Kitakyushu General Hospital; Kokura Japan

11. Biomolecular Engineering of Applied Molecular Bioscience; Ube Japan

12. Oncology and Laboratory Medicine; Yamaguchi University Graduate School of Medicine; Ube Japan

13. Translational Research and Clinical Trial Center; Hokkaido University Hospital; Sapporo Japan

14. Tokai Central Hospital; Gifu Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.12283/fullpdf

Reference30 articles.

1. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial;Douillard;Lancet,2000

2. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group;Saltz;N Engl J Med,2000

3. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

4. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11;Kawato;Cancer Res,1991

5. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes;Iyer;J Clin Invest,1998

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer;Clinical and Translational Science;2024-05

2. Cuproptosis gene‐related, neural network‐based prognosis prediction and drug‐target prediction for KIRC;Cancer Medicine;2023-12-22

3. The expanding role of gene-based prescribing for phase II drug-metabolizing enzymes;American Journal of Pharmacotherapy and Pharmaceutical Sciences;2023-12-22

4. Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity;Cancer Medicine;2022-10-29

5. The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients;Genomics & Informatics;2022-09-30